{"id":881950,"date":"2025-09-04T09:34:54","date_gmt":"2025-09-04T13:34:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/"},"modified":"2025-09-04T09:34:54","modified_gmt":"2025-09-04T13:34:54","slug":"guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/","title":{"rendered":"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>Latest algorithm (Shield V2) has sensitivity of 84% for colorectal cancer with specificity of 90%, with stage I sensitivity of 62%<\/i><\/li>\n<li><i>Performance of the Shield algorithm was validated in expanded clinical cohort derived from landmark ECLIPSE study<\/i><\/li>\n<\/ul>\n<p>PALO ALTO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the performance of the latest colorectal cancer (CRC) screening algorithm (V2) for its Shield\u2122 blood test. The study met all primary endpoints and the sensitivity of this new screening algorithm for detecting CRC was 84% with 90% specificity. Sensitivity for detection of stage I CRC was 62%.<\/p>\n<p>\n\u201cWe are pleased with the performance of the new algorithm in detecting stage I CRCs. Today\u2019s update shows yet again that Shield delivers best-in-class performance,\u201d said AmirAli Talasaz, Guardant Health co-CEO. \u201cWe will continue to leverage our first mover advantage, rapidly growing database and innovation engine to push Shield to higher levels of performance over time.\u201d<\/p>\n<p>\nThe clinical validation of the algorithm was conducted on an expanded cohort of subjects enrolled in the landmark ECLIPSE study. ECLIPSE is a 20,000+ person registrational study evaluating the performance of Shield for detecting CRC in average-risk adults that was published in <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2304714&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=The+New+England+Journal+of+Medicine&amp;index=1&amp;md5=ae5265c9b028cf04391a8f47206f67b8\">The New England Journal of Medicine<\/a>. Sensitivity for early-stage CRC was 62% for stage I and 100% for stage II. Sensitivity was 96% for stage III and 100% for stage IV. Sensitivity in detecting advanced adenomas was 13%.<\/p>\n<p>\nThe National Comprehensive Cancer Network (NCCN) recently updated its CRC Screening Guidelines to <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.guardanthealth.com%2Fpress-releases%2Fpress-releases%2F2025%2FNational-Comprehensive-Cancer-Network-NCCN-Updates-Colorectal-Cancer-Screening-Guidelines-to-Include-Shield-Blood-Based-Screening%2Fdefault.aspx&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=add+Shield&amp;index=2&amp;md5=bd0c16b0fa78f8925a5e5c739f8288ca\">add Shield<\/a> as the first blood test that is FDA approved for primary screening of CRC. Shield has also received numerous awards recognizing its innovation and power to change lives, including <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.guardanthealth.com%2Fpress-releases%2Fpress-releases%2F2025%2FGuardant-Health-Wins-Fast-Companys-2025-World-Changing-Ideas-Award-for-Shield-Blood-Test-for-Colorectal-Cancer-Screening%2Fdefault.aspx&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=Fast+Company%26%238217%3Bs+World+Changing+Ideas&amp;index=3&amp;md5=2d74d50ec29afdf4b905ab147f98f4e0\">Fast Company\u2019s World Changing Ideas<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.guardanthealth.com%2Fpress-releases%2Fpress-releases%2F2024%2FGuardant-Health-Named-to-TIMEs-List-of-the-Best-Inventions-of-2024%2Fdefault.aspx&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=TIME%26%238217%3Bs&amp;index=4&amp;md5=dd66a472a5a037a791a9fa355306e750\">TIME\u2019s<\/a> list of the Best Inventions of 2024 and was selected as a Grand Award Winner in <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.popsci.com%2Ftechnology%2Fbest-of-whats-new-2024%2F%23health&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=Popular+Science%26%238217%3Bs+Best+of+What%26%238217%3Bs+New+2024&amp;index=5&amp;md5=b185b3e996647ac04bed62228421c7f8\">Popular Science\u2019s Best of What\u2019s New 2024<\/a>.<\/p>\n<p>\nBeyond CRC screening, Guardant Health has a pipeline of activities around the Shield platform, including the Shield multi-cancer detection (MCD) test which was recently granted <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.guardanthealth.com%2Fpress-releases%2Fpress-releases%2F2025%2FFDA-Grants-Breakthrough-Device-Designation-to-Guardant-Healths-Shield-Multi-Cancer-Detection-MCD-Test%2Fdefault.aspx&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=Breakthrough+Device+Designation&amp;index=6&amp;md5=88450d92db8e94ce36bedfb1c79f37c1\">Breakthrough Device Designation<\/a> by the FDA and included in the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.guardanthealth.com%2Fpress-releases%2Fpress-releases%2F2025%2FFirst-Patient-Enrolled-in-National-Cancer-Institutes-Vanguard-Study-Evaluating-Guardant-Healths-Shield-Multi-Cancer-Detection-Test%2Fdefault.aspx&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=National+Cancer+Institute%26%238217%3Bs+Vanguard&amp;index=7&amp;md5=711cfd380dea577ab6435ffca9b5979a\">National Cancer Institute\u2019s Vanguard<\/a> study.<\/p>\n<p>\nShield is the first and only blood test that has received <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.guardanthealth.com%2Fpress-releases%2Fpress-releases%2F2024%2FGuardant-Healths-Shield-Blood-Test-Approved-by-FDA-as-a-Primary-Screening-Option-Clearing-Path-for-Medicare-Reimbursement-and-a-New-Era-of-Colorectal-Cancer-Screening%2Fdefault.aspx&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=full+FDA+approval&amp;index=8&amp;md5=dc7deb1406aa5c31d57f8b88fa3b6d0b\">full FDA approval<\/a> as a primary screening option for CRC in average-risk adults aged 45 and older and can be ordered by any prescribing healthcare provider. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ShieldCancerScreen.com&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=www.ShieldCancerScreen.com&amp;index=9&amp;md5=803bcfdbf6acc9d0b26c2d08d207800d\">www.ShieldCancerScreen.com<\/a>.<\/p>\n<p><b>About Guardant Health<\/b><\/p>\n<p>\nGuardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fguardanthealth&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=10&amp;md5=0db6a3ba2e4d972ab46d830fec1544cd\">LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FGuardantHealth&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=X+%28Twitter%29&amp;index=11&amp;md5=0f7425cdbb49a5b38cdb9ad54052929b\">X (Twitter)<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fguardanthealth&amp;esheet=54318990&amp;newsitemid=20250904017426&amp;lan=en-US&amp;anchor=Facebook&amp;index=12&amp;md5=3b13968bce0f4b8bc1ec9a512a49af62\">Facebook<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health\u2019s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health\u2019s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operation\u201d and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health\u2019s views as of any date subsequent to the date of this press release.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250904017426r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250904017426\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250904017426\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>Zarak Khurshid<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@guardanthealth.com\">investors@guardanthealth.com<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Meaghan Smith<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:press@guardanthealth.com\">press@guardanthealth.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Technology Genetics Clinical Trials Health Technology Health General Health Data Management Artificial Intelligence Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250904017426\/en\/2197105\/3\/Guardant_Health_Shield_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test Latest algorithm (Shield V2) has sensitivity of 84% for colorectal cancer with specificity of 90%, with stage I sensitivity of 62% Performance of the Shield algorithm was validated in expanded clinical cohort derived from landmark ECLIPSE study PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211; Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the performance of the latest colorectal cancer (CRC) screening algorithm (V2) for its Shield\u2122 blood test. The study met all primary endpoints and the sensitivity of this new screening algorithm for detecting CRC was 84% with 90% specificity. Sensitivity for detection of stage I CRC was 62%. \u201cWe &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-881950","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test Latest algorithm (Shield V2) has sensitivity of 84% for colorectal cancer with specificity of 90%, with stage I sensitivity of 62% Performance of the Shield algorithm was validated in expanded clinical cohort derived from landmark ECLIPSE study PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211; Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the performance of the latest colorectal cancer (CRC) screening algorithm (V2) for its Shield\u2122 blood test. The study met all primary endpoints and the sensitivity of this new screening algorithm for detecting CRC was 84% with 90% specificity. Sensitivity for detection of stage I CRC was 62%. \u201cWe &hellip; Continue reading &quot;Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-04T13:34:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250904017426r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test\",\"datePublished\":\"2025-09-04T13:34:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/\"},\"wordCount\":829,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250904017426r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/\",\"name\":\"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250904017426r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-09-04T13:34:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250904017426r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250904017426r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/","og_locale":"en_US","og_type":"article","og_title":"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test - Market Newsdesk","og_description":"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test Latest algorithm (Shield V2) has sensitivity of 84% for colorectal cancer with specificity of 90%, with stage I sensitivity of 62% Performance of the Shield algorithm was validated in expanded clinical cohort derived from landmark ECLIPSE study PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211; Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the performance of the latest colorectal cancer (CRC) screening algorithm (V2) for its Shield\u2122 blood test. The study met all primary endpoints and the sensitivity of this new screening algorithm for detecting CRC was 84% with 90% specificity. Sensitivity for detection of stage I CRC was 62%. \u201cWe &hellip; Continue reading \"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-04T13:34:54+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250904017426r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test","datePublished":"2025-09-04T13:34:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/"},"wordCount":829,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250904017426r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/","name":"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250904017426r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-09-04T13:34:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250904017426r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250904017426r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/guardant-health-announces-clinical-result-update-for-shield-blood-based-colorectal-cancer-screening-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881950","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=881950"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881950\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=881950"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=881950"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=881950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}